Long-term follow-up for cell and gene therapy participants
Part of Cancer, Digestive system, Kidney & urinary clinical trials.
This study is a long-term follow-up for people who have already received a cell or gene therapy in a previous AstraZeneca trial. It helps researchers monitor your health over time to make sure the therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already received a cell or gene therapy (a treatment that uses modified cells or genes) in another AstraZeneca study.
- You are willing to sign a written consent form to participate in this follow-up study.
- There are no other restrictions—most people who meet these two conditions can join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
This study is for people who already received the experimental treatment azer-cel in a previous trial. It will follow you over the long term to see how you're doing and monitor any lasting effects.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.